Parkinson's disease (PD) belongs to the main group of neurodegenerative disorders, being the second most common neurodegenerative disorder, that was primarily characterized by motor signs including bradykinesia, resting tremor and muscle rigidity. This concept has been changed mainly in the 21st century and, at this moment, PD is regarded as much a non-motor disorder [1, 2, 19].

The importance of non-motor symptoms (NMS) for patients with Parkinson's disease was highlighted by reports which have suggested the serious social and economic consequences related to NMS, frequently causing hospitalization and institutionalization [3,4].

NMS include 10 domains ranging from dysfunction of gastrointestinal tract to miscellaneous (diplopia, weight loss), and – as reported by a European study, more than 90% of patients did not mention or discuss the NMS they are experiencing until the clinicians became aware of them [5]. The presence of NMS in the clinical presentation of PD patients has been accompanied by a trend towards a more patients-centered approach to the diagnosis and treatment of the disease [6].

Levodopa, the precursor of dopamine, is an aromatic amino acid that was introduced into the treatment of patients in the first years of 1960s and is, until now, considered the gold standard among antiparkinsonian drugs [7]. It has a marked symptomatic effect on all components of the cardinal parkinsonian motor signs, but to a lesser extent, on non-motor symptoms [8].

Until now, there are two manner in which levodopa can be administrated: oral administration and intrajejunal infusion.

In our study, we wanted to evaluate the presence of gastrointestinal dysfunction in patients with PD and the degree of these dysfunction depending on the route of levodopa administration.

**Experimental part**

**Methods and materials**

31 patients diagnosed with advanced Parkinson’s disease established by Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s disease were included in this study [9]. They were divided in 2 groups: group A composed of 14 patients (10 men and 4 women, with a mean age 69.7) that were treated with oral levodopa and 17 patients (8 men and 9 women, with a mean age 65.3) treated with levodopa/carbidopa intrajejunal infusion.

All patients were evaluated in best on state for motor status using Unified Parkinson’s Disease Rating Scale (UPDRS) part 3 (motor part), healthy related quality of life with PDQ-8 (8-item Parkinson’s Disease Questionnaire) [10].

To evaluate the non-motor symptoms, each patient was assessed by Non-motor Symptoms Questionnaire for Parkinson’s Disease regarding the dysfunction of gastrointestinal tract. The results of our study indicated that there is a different distribution of the digestive dysfunction between the two groups of patients. The study indicate that the constipation was more frequent in those patients with oral medication.

Keywords: levodopa, oral administration, intrajejunal gel, Parkinson’s disease
symptoms. It is a self-assessing tool that includes 30 questions covering 10 different domains ranging from gastrointestinal to miscellaneous [1].

The gastrointestinal domain includes dribbling of saliva, ageusia, dysphagia/choking, vomiting/nausea, constipation, unsatisfactory voiding of bowel and fecal incontinence. This questionnaire must be completed by the patient, checking the no or yes box. We rated 0 point if the patient’s answer was no and 1 point if the patient’s answer was yes.

The statistical analysis was made using IBM SPSS Statistics V20. We performed both descriptive and exploratory data analysis. For comparisons we used one tailed student t-test and for correlation - Pearson R test, with the statistical significance established when p<0.05.

Results and discussions
The analysis of the digestive domain showed a distinct distribution in the two groups.

We can see in the graph below that except the ageusia, all the digestive symptoms have an increased frequency in patients treated with oral levodopa.

The greatest difference appears to be on the vomiting/nausea, constipation and the unsatisfactory voiding of bowal (fig. 1).

On the other side, in group B the Quality of life decreased as the prevalence of digestive symptoms increased. That showed a positive correlation with p=0.02 (table 3, fig. 4).

We compared the prevalence of digestive symptoms with the motor dysfunction, assessed with UPDRS part III, in the 2 groups.

---

**Results and discussions**

The analysis of the digestive domain showed a distinct distribution in the two groups.

We can see in the graph below that except the ageusia, all the digestive symptoms have an increased frequency in patients treated with oral levodopa.

The greatest difference appears to be on the vomiting/nausea, constipation and the unsatisfactory voiding of bowal (fig. 1).

On the other side, in group B the Quality of life decreased as the prevalence of digestive symptoms increased. That showed a positive correlation with p=0.02 (table 3, fig. 4).

We compared the prevalence of digestive symptoms with the motor dysfunction, assessed with UPDRS part III, in the 2 groups.

---

**Table 1**

<table>
<thead>
<tr>
<th>Digestive_symptoms</th>
<th>Test Value</th>
<th>df</th>
<th>Sig. (2-tailed)</th>
<th>Mean Difference</th>
<th>95% Confidence Interval of the Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digestive_symptoms</td>
<td>10.413</td>
<td>10</td>
<td>.000</td>
<td>2.139</td>
<td>1.29 - 1.69</td>
</tr>
<tr>
<td>Administration form</td>
<td>0.010</td>
<td>10</td>
<td>.991</td>
<td>.048</td>
<td>.38 - .73</td>
</tr>
</tbody>
</table>

*Fig. 2. Comparison between digestive symptoms in group A and B*

| Table 2
| PEARSON CORRELATION TABLE BETWEEN DIGESTIVE SYMPTOMS AND QOL IN GROUP A |
|-----------------------------|-----------------------------|
| Digestive symptoms Pearson Correlation | Digestive symptoms PDQ8 N |
| Digestive symptoms | .297 | 14 |
| PDQ8 | .020 | 14 |

*Fig. 3. Correlation between digestive symptoms and Qol in group A*

| Table 3
| PEARSON CORRELATION TABLE BETWEEN DIGESTIVE SYMPTOMS AND QOL IN GROUP B |
|-----------------------------|-----------------------------|
| Digestive symptoms Pearson Correlation | Digestive symptoms PDQ8 N |
| Digestive symptoms | .415 | 14 |
| PDQ8 | .020 | 14 |

*Correlation is significant at the 0.05 level (2-tailed).*

*Fig. 4. Correlation between digestive symptoms and Qol in group B*
Group A did not present a difference between the motor and digestive dysfunction, in the second group there was a difference, but not statistically significant with P=0.06. Digestive dysfunction plays an important role in PD patients and it is present from the early stage of the disease [12]. Early involvement of the gut is considered to be a possible pre-symptomatic state of PD [13]. Constipation is considered to be present in over 50% of PD patients. It is used as a potential biomarker for prodromal Parkinson’s disease [14]. L-dopa administration represent the gold standard in PD treatment. Sustained striatal dopamine level with continuous L-dopa/carbidopa administration showed superior to oral medication. It improved both motor and non-motor symptoms [15]. Our study also showed decreased trend in the frequency of digestive symptoms of these patients when compared with patients on oral medication. The markers that contribute to decreased the quality of life is stigma, memory loss, motor impairment and digestive dysfunction, especially drooling [16,17]. In our analysis the digestive dysfunction only correlated with the quality of life in patients with continuous administration of L-dopa/carbidopa. The autonomic features are heterogeneous distributed and as in the larger studies, in our study it is not correlate with the motor symptoms [18].

Conclusions
Our study indicates that the frequency of digestive symptoms is hire in patients with oral medication, especially vomiting/nausea, constipation and the unsatisfactory voiding of bowel.

References
8. Ward, A.-L., and Hospital, T., Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: 12-month interim outcomes-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/), 2015.

Manuscript received: 21.12.2018